drug interaction(s) of SGLT-2 inhititor (flozin) in combination with GLP1-agonist

^[1]^[2]

Drug interactions

GLP-1 agonists (incretin mimetics) & SGLT-2 inhititor (flozin) have additive benefits for cardiovascular disease & diabetic nephropathy^[1]
robust improvements in cardiac & renal outcomes with SGLT-2 inhibitors, independent of GLP-1 agonist use^[2]

↑ ^1.0 ^1.1 Simms-Williams N et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: Population based cohort study. BMJ 2024 Apr 25; 385:e078242. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38663919 PMCID: PMC11043905 Free PMC article https://www.bmj.com/content/385/bmj-2023-078242
↑ ^2.0 ^2.1 Apperloo EM, Neuen BL, Fletcher RA et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: A SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2024 Aug; 12:545-557. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38991584 https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00155-4/abstract
Escobar Cervantes C. SGLT2 inhibitors and GLP-1 receptor agonists: The definitive combination? Lancet Diabetes Endocrinol 2024 Aug; 12:507. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38991583 https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00183-9/abstract